Bishton MJ - Search Results

1

Clinical studies of histone deacetylase inhibitors.

Prince HM, Bishton MJ, Harrison SJ. Prince HM, et al. Among authors: bishton mj. Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509172 Review.

2

Spinal epidural lipomatosis in myeloma.

Liew MS, Bishton MJ, Januszewicz H, Alatakis S, Prince HM. Liew MS, et al. Among authors: bishton mj. Leuk Lymphoma. 2007 Oct;48(10):2068-70. doi: 10.1080/10428190701593651. Leuk Lymphoma. 2007. PMID: 17852706 No abstract available.

3

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM. Bishton M, et al. Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. doi: 10.1586/14737140.7.10.1439. Expert Rev Anticancer Ther. 2007. PMID: 17944568 Review.

4

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.

Prince HM, Bishton M, Harrison S. Prince HM, et al. Leuk Lymphoma. 2008 Mar;49(3):385-7. doi: 10.1080/10428190801950058. Leuk Lymphoma. 2008. PMID: 18297514

5

Histone deacetylase inhibitors in lymphoma and solid malignancies.

Rasheed W, Bishton M, Johnstone RW, Prince HM. Rasheed W, et al. Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32. doi: 10.1586/14737140.8.3.413. Expert Rev Anticancer Ther. 2008. PMID: 18366289 Review.

6

Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set.

Bishton MJ, Hicks RJ, Prince HM, Ritchie DS, Wolf M, Seymour JF. Bishton MJ, et al. Leukemia. 2008 Dec;22(12):2259-60; author reply 2260-1. doi: 10.1038/leu.2008.116. Epub 2008 May 15. Leukemia. 2008. PMID: 18480835 No abstract available.

7

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.

Prince HM, Bishton MJ, Johnstone RW. Prince HM, et al. Among authors: bishton mj. Future Oncol. 2009 Jun;5(5):601-12. doi: 10.2217/fon.09.36. Future Oncol. 2009. PMID: 19519200 Review.

8

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Dickinson M, et al. Br J Haematol. 2009 Oct;147(1):97-101. doi: 10.1111/j.1365-2141.2009.07837.x. Epub 2009 Aug 5. Br J Haematol. 2009. PMID: 19663825 Free article. Clinical Trial.

9

Light chain deposition disease presenting as massive hepatomegaly.

Nath SV, Peiris M, Bishton MJ, Maxwell E, Prince HM. Nath SV, et al. Among authors: bishton mj. Pathology. 2010 Apr;42(3):307-10. doi: 10.3109/00313021003631171. Pathology. 2010. PMID: 20350234 No abstract available.

10

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).

Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince HM. Burbury KL, et al. Among authors: bishton mj. Ann Hematol. 2011 Jul;90(7):847-9. doi: 10.1007/s00277-010-1099-6. Epub 2010 Oct 15. Ann Hematol. 2011. PMID: 20949272 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters